Results 101 to 110 of about 4,593,278 (410)

Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities [PDF]

, 2017
© 2017 The Author(s). Anti-cancer therapies including chemotherapy aim to induce tumour cell death. Cell death introduces alterations in cell morphology and tissue micro-structures that cause measurable changes in tissue echogenicity.
A Ahmed, A Guimond, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, B Banihashemi, B Fisher, B Ganeshan, BS Garra, BS Pio, BT Hennessy, C-P Chou, D Sethi, DA Mankoff, EJ Feleppa, EJ Feleppa, F Tixier, FJ Esteva, FL Lizzi, FT D’Astous, G Berger, G Minckwitz von, GJ Czarnota, GJ Czarnota, GN Hortobagyi, H Haibo, H Tadayyon, H Tadayyon, H Tadayyon, HC Kim, HM Kuerer, II Wistuba, J Czernin, JB Nikas, JPB O’Connor, K Brindle, K Sikora, K Suzuki, KA Wear, KM Brindle, KN Ogston, L Sannachi, LX Yao, M Dowsett, M Vaidya, MF Insana, ML Oelze, ML Oelze, N Duric, O Falou, O Falou, QH Huang, R Tiling, RM Haralick, RM Vlad, RM Vlad, SH Giordano, SH Giordano, SJ Cleator, SM Scholl, T Cover, TJ Larkin, U McDermott, V Goh, V Guarneri, X Li, Y Labyed   +70 more
core   +2 more sources

Non‐Invasive Tumor Budding Evaluation and Correlation with Treatment Response in Bladder Cancer: A Multi‐Center Cohort Study

Advanced Science, EarlyView.
This study introduces a deep learning model that predicts tumor budding (TB) status in bladder cancer through the analysis of CT images. The model effectively identifies patients with high TB status, correlating with poorer prognosis and reduced responsiveness to neoadjuvant chemoimmunotherapy. This tool offers significant potential to inform prognosis
Xiaoyang Li, Chen Zou, Chunhui Wang, Cheng Chang, Yi Lin, Shuai Liang, Haoran Zheng, Libo Liu, Kai Deng, Lin Zhang, Bohao Liu, Mingchao Gao, Peicong Cai, Jianwen Lao, Longhao Xu, Daqin Wu, Xiao Zhao, Xiao Wu, Xinyuan Li, Yun Luo, Wenlong Zhong, Tianxin Lin   +21 more
wiley   +1 more source

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae [PDF]

arXiv, 2021
We propose to apply stacked CA using contribution biplots as a tool to explore differences in AE data among treatments in clinical trials. We defined five levels of refinement for the analysis based on data derived from the Common Terminology Criteria for Adverse Events (CTCAE) grades, domains, terms and their combinations.
arxiv  

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Arnold, Dirk, Brenner, Baruch, Galle, Peter R., Gockel, Ines, Klautke, Gunther, Lang, Hauke, Möhler, Markus, Roessler, Hans-Peter, Rödel, Claus, Schimanski, Carl Christoph, Schmidberger, Heinz, Thomaidis, Thomas, Trarbach, Tanja   +12 more
core   +1 more source

Dual Role of CRABP2 in Colorectal Cancer: Oncogenesis via Nuclear RB1 and Cytoplasmic AFG3L2/SLC25A39 Axis, While Limiting Liver Metastasis through Cytoplasmic AFG3L2/PINK1/Parkin‐Mediated Mitophagy

Advanced Science, EarlyView.
CRABP2 plays a dual role in colorectal cancer: it promotes proliferation and suppresses apoptosis through the nuclear CRABP2/RB1 axis and the cytoplasmic AFG3L2/SLC25A39 axis. Meanwhile, it inhibits colorectal liver metastasis via AFG3L2/PINK1/Parkin‐mediated mitophagy.
Chuanxin Tian, Sheng Yang, Chuan Zhang, Renzhong Zhu, Chen Chen, Xiaowei Wang, Dongsheng Zhang, Qingyang Sun, Hengjie Xu, Hongxu Nie, Yue Zhang, Dongjian Ji, Junwei Tang, Kangpeng Jin, Yueming Sun   +14 more
wiley   +1 more source

Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma

Journal of the National Cancer Center, 2022
: Objective: This is a prospective, single-arm, phase Ib study to evaluate the safety and efficacy of camrelizumab combined with chemotherapy and apatinib as neoadjuvant therapy for locally advanced thoracic esophageal squamous cell carcinoma (ESCC ...
Zhen Wang, Xiankai Chen, Yong Li, Jianjun Qin, Yuan Fang, Zhaoyang Yang, Yan Fang, Dong Qu, Ruixiang Zhang, Qingfeng Zheng, Xiaozheng Kang, Liyan Xue, Jing Huang, Yin Li, Jie He   +14 more
doaj  

Placement of a self-expandable metallic stent as a bridge to surgery for large bowel obstruction induced by effective neoadjuvant therapy: report of three cases

Surgical Case Reports, 2018
Background Self-expandable metallic stent placement is a widely performed palliative procedure or bridge to surgery for obstructive colorectal cancer. However, the feasibility of this procedure for large bowel obstruction induced by effective neoadjuvant
Fumihiko Ando, Akihisa Matsuda, Masao Miyashita, Satoshi Matsumoto, Nobuyuki Sakurazawa, Youichi Kawano, Hiroshi Yoshida   +6 more
doaj   +1 more source

Magnetic resonance tumor regression grade (MR-TRG) to assess pathological complete response following neoadjuvant radiochemotherapy in locally advanced rectal cancer [PDF]

, 2017
This study aims to evaluate the feasibility of a magnetic resonance (MR) automatic method for quantitative assessment of the percentage of fibrosis developed within locally advanced rectal cancers (LARC) after neoadjuvant radiochemotherapy (RCT). A total
Bellini, D, Caruso, D, Caterino, Martina, Ciolina, M, De Santis, D, Laghi, A., Marzi, S, Musio, Daniela, Picchia, S, Rengo, M, Tombolini, V   +10 more
core   +1 more source

Plasma DNMT1 Activity for Assessing Tumor Burden and Predicting Neoadjuvant Therapy Response in Breast Cancer

Advanced Science, EarlyView.
In this work, a detection method is presented for the activity of plasma DNA methyltransferase 1 (DNMT1), namely DNMT1 Identification by Variable Activity (DIVA). DIVA can detect plasma DNMT1 at levels as low as 10−7 U mL−1, also it successfully evaluated tumor burden and predicted the neoadjuvant therapy responses of breast cancer patients.
Yingran Wang, Guozhi Zhang, Zhizhao Zhang, Mengsi Zhang, Jiao Chen, Ke Wang, Lu Liu, Jing Bao, Ming Chen, Xiaowei Qi, Mingxuan Gao   +10 more
wiley   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

BJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund, F. Celebioglu, T. Hatschek, J. Frisell, J. de Boniface   +4 more
wiley   +1 more source